К содержанию
Dr. Tara EinullaevaMedical oncologist

Cancer glossary

EGFR mutation in lung cancer: what your test result means

What an EGFR mutation on your report means: common variants (exon 19, exon 21, exon 20), who needs the test, and how the result shapes lung cancer treatment.

Written and medically reviewed by

Dr. Tara Einullaeva

Medical oncologist, 9 years in practice. Credentials · reviewed 17 October 2026

In short

EGFR is the gene for a receptor that signals the cell to grow. In non-small cell lung cancer it can carry mutations that respond to EGFR inhibitor pills, which is why this test is done before treatment starts.

How it appears in your report

  • ‘EGFR exon 19 deletion detected’ — one of the two main ‘sensitizing’ mutations.
  • ‘EGFR: L858R mutation (exon 21)’ — the other main one.
  • ‘EGFR exon 20 insertion’ — a distinct group with its own treatment.
  • ‘No mutations detected in the EGFR gene’ — negative for the variants tested.

The method matters: PCR checks a predefined set of mutations, while NGS checks dozens of genes at once. The sample can be tumor tissue or blood (liquid biopsy).

What it means

Result What it usually means
Exon 19 or exon 21 mutation the tumor is usually sensitive to EGFR inhibitors
Uncommon mutations (G719X, L861Q, S768I) targeted options exist for these too
Exon 20 mutation different drugs are needed
No mutation treatment is guided by PD-L1 and other markers

According to the American Cancer Society, EGFR mutations are more common in people who don’t smoke, in women and in people of Asian descent. Still, smoking history, sex and age cannot rule out a mutation, so everyone who meets the criteria should be tested.

Does it affect treatment

Yes, directly. With an EGFR mutation, first-line treatment for advanced disease is usually targeted therapy rather than immunotherapy. Don’t confuse this with colorectal cancer: there, anti-EGFR antibodies are used not because of an EGFR mutation but when there are no KRAS or NRAS mutations. Your treating doctor chooses the specific drug.

Questions to ask your doctor

  • Which method was used for EGFR, and which variants did the test cover?
  • If there is a mutation, which one exactly, and which drugs work for it?
  • If the blood test was negative, do I need a tissue test?

More in the articles on mutations in lung cancer and on targeted therapy. If you were diagnosed recently, I can check whether all the tests have been done.

Sources

  1. Targeted Drug Therapy for Non-small Cell Lung Cancer — American Cancer Society, 2025
  2. Tests for Lung Cancer — American Cancer Society, 2024
  3. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers — ESMO, 2020

FAQ

Related terms

This is reference information and not a substitute for medical advice. Your doctor interprets each value in the context of your whole situation.

Related articles

All blog articles